Sanofi CEO Says Genzyme Offer May Be Extended

Sanofi Aventis Chief Executive Chris Viehbacher said in an interview that the French pharmaceuticals group's offer for Genzyme could be extended for a third time, beyond the Feb. 15 deadline.

Asked by La Tribune newspaper about the deadline, Viehbacher said: "It is a possibility, there are no limits on takeover offers in the United States."

He added: "It is normal to spend time on an operation of $18.5 billion."

Viehbacher's interview is to be published in La Tribune business newspaper on Thursday and was made available late on Wednesday.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.